Unknown PHASE2 INTERVENTIONAL 1-arm NCT03736330

A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma

A Study of Anti-PD-1( Pembrolizumab) Combinations of D-CIK (Cytokine-induced Killer Cells Are Stimulated Using Mature Dendritic Cells) Immunotherapy and Axitinib in Advanced Ranal Carcinoma

Sponsor: Sun Yat-sen University

Conditions Renal Cancer Metastatic

Interventions Combinations treatment

Updated 5 times since 2018 Last updated: Nov 8, 2018 Started: Sep 8, 2018 Primary completion: Oct 8, 2020 Completion: Nov 8, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Renal Cancer Metastatic, this trial is ongoing. The trial is conducted by Sun Yat-sen University and has accumulated 5 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Jan 2022 [monthly]

Recruiting PHASE2
Dec 2018 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Sep 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China